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ABSTRACT 
Recombinant activated factor VII (rFVIIa) is registered for patients with rare haematological 
disorders, but is used ‘off-label’ in many other situations, including intracranial 
haemorrhage, cardiac surgery, trauma, transplantation and prostatectomy. Lack of 
systematic evidence to support these off-label uses has not slowed the growth of off-label 
prescribing of rFVIIa. We use the case of rFVIIa to illustrate the issues raised by off-label 
prescribing, and the kind of impasse that can arise when views about evidence, expertise 
and clinical necessity are in conflict. We argue that clinicians, hospital drug committees and 
regulators all need to acknowledge the complexity of prescribing decisions, and ensure that 
decisions to prescribe off-label are sufficiently justified. 
 
Introduction 
‘Off-label prescribing’ refers to the prescription of a pharmaceutical agent in a manner that 
is not consistent with indications approved by a regulatory agency, such as the Food and 
Drug Administration in the United States or the Therapeutic Goods Administration (TGA) in 
Australia. The distinction between on-label and off-label prescribing is essentially a 
statement about evidence and authority. ‘On-label’ uses are those that have been 
determined following formal assessment of safety and efficacy data from clinical trials 
according to standards demanded by the drug regulator. When a clinician prescribes a 
medication contrary to approved indications (i.e. for a different indication, patient age 
range, dose or route), this constitutes an off-label use.1 
In recent years, off-label prescribing has attracted significant debate. On the one hand, it is 
argued that off-label prescribing can promote clinical innovation and provide options for 
patients for whom there are no other alternatives.2,3 Arguments in favour of off-label 
prescribing also note that adding new information to a label is a costly and time-consuming 
process. Thus, while it is often in a drug company's interests to extend the indications for its 
products, information that could be beneficial to physicians and patients might in some 
cases be of only limited value to the pharmaceutical industry, and therefore unlikely to ever 
be added to the label. Indeed, in some cases supporting research into off-label indications 
may be counterproductive to the industry as more controlled studies might negate the 
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efficacy claims that smaller, less formalised studies may make. On the other hand, a number 
of concerns have been raised about off-label prescribing, including that it is not (always) 
evidence based, that it undermines the regulatory system, that it is costly, that it puts 
patients at risk2,3 and that it results from the promotional activities of pharmaceutical 
companies anxious to extend the market for their product.4 It is also claimed, although very 
difficult to prove, that excessive off-label drug use could impact on pharmaceutical 
innovation as physicians may be less likely to enrol patients in clinical trials of investigational 
drugs if patients have off-label treatment options.5 Those with concerns about off-label 
prescribing have generally supported robust controls of off-label drug promotion and 
advertising, and have called for measures to further restrict the ability of physicians to 
prescribe drugs off-label.6,7 
Off-label prescribing is not an uncommon event,1,8 with recent research demonstrating 
extensive off-label prescribing of agents, including anti-epileptics (used as mood stabilisers 
and to treat neuropathic pain), anti-psychotics (used to treat delirium) and anti-rejection 
medications used for (non-transplant-related) immunological conditions. An extensive study 
of office-based physicians in the United States examined prescribing patterns for 160 
medicines and showed that 21% of all prescriptions were off-label, 73% of which were 
classified by the authors as having little or no scientific support.8 In a study of a specialist 
oncology centre in Australia, 35% of prescriptions were found to be off-label.9 Off-label 
prescribing is also common in geriatric medicine10 and obstetrics,11 and in the treatment of 
patients with rare diseases.12 Off-label prescribing is particularly common in paediatrics, 
with one study suggesting that well over half of all paediatric prescriptions are off-label.13 
This is not surprising given that many medicines are not tested in children and cannot, 
therefore, be formally registered for paediatric indications. 
In many instances, clinicians may not be aware that they are engaging in off-label 
prescribing. A study aimed at testing the knowledge of prescribers about off-label 
indications of commonly-prescribed drugs found that in only just over 50% of cases could 
physicians accurately identify an off-label use and that in 41% of cases, physicians believed 
that at least one drug-indication pair that had uncertain or no supporting evidence was 
regulator approved.14 
The case of off-label prescribing of recombinant factor VIIa (rFVIIa) provides a good 
illustration of these issues, and of the impasse that can result from disagreements about off-
label prescribing. 
 
 
The story of off-label rFVIIa 
rFVIIa (NovoSeven – NovoNordisk; generic name: epticog alpha) is a powerful coagulant. It is 
registered by the therapeutic goods administration (TGA) for the treatment of haemorrhage 
in factor VII deficiency, Glanzmann's thrombasthaenia, and in patients with haemophilia 
with inhibitors to factor VIII or IX. Because factor VII is a protein that is involved in normal 
coagulation, rFVIIa is also widely used off-label in a broad range of settings in which 
prevention or control of bleeding is paramount, such as cardiac surgery, intracerebral 
haemorrhage, postpartum haemorrhage and thoraco-abdominal trauma.15–19 Recent 
studies in the United States have noted a dramatic increase in off-label use of rFVIIa, which 
was almost non-existent in 2000 and now constitutes more than 97% of usage of rFVIIa.20 
The story of this dramatic rise in off-label prescribing – and the involvement of its 
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manufacturer – is illustrative. In 1999, a research letter was published in the Lancet, which 
reported that traumatic bleeding had been successfully treated with rFVIIa.21 Referenced in 
this letter was a symposium held the same year by the manufacturers of the drug (Novo 
Nordisk) on the treatment of bleeding and thrombotic disorders. At this symposium it was 
reported that rFVIIa had been used for a range of indications, including cardiac surgery. In 
the following years, a series of articles touting the effectiveness of rFVIIa in controlling 
bleeding in traumatic haemorrhage,22 some cardiac surgery,23 and severe bleeding 
associated with disseminated intravascular coagulation24 were published. Around this time, 
the off-label prescribing of rFVIIa began to rise dramatically.20 Published studies of the 
efficacy of off-label rFVIIa were conflicting, with some studies suggesting that rFVIIa was 
effective in the management of intracerebral haemorrhage, and bleeding in cardiac surgery, 
liver surgery, postpartum haemorrhage and trauma, and others suggesting that it had no 
benefit.25,26 Early studies of the safety of off-label rFVIIa, particularly with respect to its 
likelihood of causing thromboembolic events, were also contradictory.27,28 Despite 
uncertainty regarding the risks and benefits of rFVIIa, off-label prescribing has risen 
dramatically over the last decade, with some estimates suggesting that off-label prescribing 
of rFVIIa has increased 140-fold over this time.20 
Importantly, however, recent systematic reviews and meta-analyses of the off-label use of 
rFVIIa for cardiac surgery, intracranial haemorrhage, trauma, liver transplant and 
prostatectomy, have shown that it does not lead to a reduction in overall mortality,29,30 
but may be associated with a small (and generally non-significant) reduction in haematoma 
expansion in intracerebral haemorrhage and adult respiratory distress syndrome in trauma. 
These reviews have also noted an increase in the risk of arterial thromboembolism when 
rFVIIa is used off-label – particularly in cardiac surgery and intracerebral haemorrhage.29 
While most studies included in these reviews have been conducted in the United States and 
Western Europe, the results are relevant to practice in Australia and New Zealand as 
research from Australia has established that rFVIIa is widely prescribed in Australian 
hospitals – particularly in cardiac surgery and trauma.31 
The authors of the most recent systematic review29 and the editorial that accompanied it32 
concluded that off-label use of rFVIIa is unwarranted and that rFVIIa should only be 
prescribed off-label in the context of clinical trials. This conclusion, however, has been met 
with significant resistance from a subset of clinicians.33,34 The arguments given for and 
against off-label use of rFVIIa illustrate both the reasons why physicians might prescribe off-
label and the limitations of systems of evidence that fail to take account of the reasons why 
physicians prescribe the medications they do. 
 
Arguments for and against off-label use of rFVIIa 
Those in favour of off-label prescribing of rFVIIa generally argue that they and their 
colleagues have observed clinical benefit when using rFVIIa, that surrogate end-points, such 
as reductions in re-operation or blood loss may be as significant as overall mortality, and 
that observations made in specific clinical contexts might be more relevant than the 
composite results of clinical trials. They also make reference to the fact that they have little 
else to offer their patients in situations of overwhelming blood-loss, and that ‘even if the 
safety data from existing randomised trials do apply . . . this risk is likely dwarfed by the risk 
of allowing blood loss to continue unabated’.33 Opponents of off-label prescribing of rFVIIa, 
on the other hand, argue that evidence-based medicine should trump both ‘emotion’ and 
clinical experience, and that composite evidence provided by a systematic review should 
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take precedence over the results of individual studies. Indeed, Jerry Avorn and Aaron 
Kesselheim, the authors of an editorial accompanying the systematic review in the Annals of 
Internal Medicine argued that, in light of emerging evidence, ‘physicians who persist in 
(using rFVIIa off-label) in the face of clear evidence of inutility and harm could be subject to 
civil action by the affected patients or their heirs.’32 In their editorial Avorn and Kesselheim, 
like others before them, also made note of the high costs of rFVIIa (in Australia, the current 
price of rFVIIa is $1169 per 1 mg, and doses range from 50 to 100 mcg/kg, so for a 70 kg man 
a single dose of rFVIIa would cost between $4091 and $8183, and two doses would cost 
$8183 to $16 366) and the possible role of the manufacturer (Novo Nordisk) in promoting 
off-label use of rFVIIa. Novo Nordisk was sanctioned by Medicines Australia in 2004 for 
inappropriate marketing of rfVIIa35 and recently settled (for $25 million) a civil lawsuit for 
improper marketing of rFVIIa, appearing to vindicate Avorn's and Kesselheim's contention 
that in this case, as in many others, off-label prescribing may occur as a direct result of the 
promotional activities of the pharmaceutical industry.36 A recent study published in 2010 by 
Spurling et al. supports this view, having observed a correlation between industry promotion 
and prescribing patterns.37 
 
Implications: taking responsibility for off-label prescribing 
The case of rFVIIa illustrates that debates about off-label prescribing are not simply a matter 
of different interpretations of data from clinical trials, but occur as a result of the complex 
interplay of different influences on prescribing. It is unlikely that the debate about off-label 
prescribing will ever be fully resolved as clinical trials and regulatory labels will never be able 
to capture all possible uses of a medicine for all possible patient groups. 
What matters more is that all stakeholder groups are aware of the issues surrounding off-
label prescribing, and of their responsibilities for ensuring that off-label prescribing is as 
safe, effective and cost-effective as possible. 
First, professional bodies have a responsibility for identifying instances of off-label 
prescribing and generating clinical practice guidelines that take account of off-label uses of 
medicines. However, just as it would be impossible to approve a drug for all the medical 
conditions it might treat, so too it would be impossible to develop clinical guidelines for 
every possible off-label use. For this reason, clinicians and hospital drug committees also 
have an important role to play. 
Clinicians need to be conscious of the fact that they often prescribe off-label and that all 
such decisions can have serious implications – particularly when evidence of efficacy and/or 
safety is lacking. Once this has been acknowledged, clinicians will be in a better position to 
reflect on their own prescribing practices and ask themselves: ‘Am I privileging the values of 
evidence-based medicine, or am I privileging other factors, such as common professional 
practice, clinical impression, physiological rationale?’ And ‘To what degree has my decision 
to prescribe this agent been influenced by drug company marketing?’ Whatever the answer, 
it is then the clinician's responsibility to acknowledge the implications of his or her decision 
for the patient as well as for the healthcare system and (re)consider whether their off-label 
use of this medication is justifiable. The clinician also needs to consider whether and how 
the patient is informed about off-label use – a complex ethical and legal issue given that 
some off-label uses are supported by substantial bodies of evidence whereas others are 
closer to being ‘experimental’.1 In this regard, it is noteworthy that legal analysis suggests 
that although off-label prescribing may increase the chance of liability, this can be reduced 
by taking appropriate measures such as: informing the patient that the drug is being used 
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off-label; ensuring the motivation for use is in the best interest of the patient; basing the 
decision on sound expert opinion; supporting use with reputable peer-reviewed literature; 
and ensuring the decision would be generally supported by local colleagues.12,38 Given 
these complexities, some have argued that the role of clinical pharmacologists should be 
strengthened as they are best positioned to make a judgement about the most appropriate 
and cost-effective treatment options.39 
There is also an important role for hospital drug committees. While drug committees 
currently provide an important check on off-label prescribing of medications, particularly 
expensive medications, there is a pressing need to clarify and standardise the criteria for 
assessment of requests for off-label prescribing. And, as is the case with the decisions made 
by individual clinicians, these criteria must acknowledge that published evidence is not 
always complete or adequate (i.e. that lack of evidence is not evidence of lack) and that off-
label prescribing is driven not only by evidence but by clinical necessity, physiological and 
therapeutic rationale and by the drive both to innovate and to provide care for people for 
whom there are few alternatives. But while clinicians and hospital drug committees are 
immediately responsible for the day to day decisions about off-label prescribing, it is also up 
to regulators to take a broader view and to ensure that off-label prescribing in the absence 
of high quality evidence and/or another compelling rationale is managed appropriately. The 
civil lawsuit against Novo Nordisk underscores the need for better monitoring of off-label 
drug uses and pharmaceutical industry promotion of off-label prescribing. This should aim at 
identifying and investigating any dramatic unexplained increases in off-label prescribing 
before such practices diffuse throughout, and become entrenched within, the system. The 
medical community and health regulators could work together to establish such 
mechanisms. 
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